Rallybio Corp.’s story began when in 2018 a trio of former Alexion Pharmaceuticals Inc. executives, Martin Mackay, Stephen Uden and Jeff Fryer, decided to create their own firm after having collaborated on rare disease drug development since 2013.
Rallybio Looks To Deals To Grow ‘Transformative’ Rare Disease Pipeline
Emerging Company Profile: Armed with the insight of its ex-Alexion leaders, Rallybio is eyeing a spate of deals to develop and commercialize transformative drugs for rare diseases.
